Actelion Pharmaceuticals Canada Inc.

Actelion Pharmaceuticals Canada Inc.

July 26, 2012 15:35 ET

British Columbia Approves PharmaCare Coverage for Toctino® Alitretinoin

LAVAL, CANADA--(Marketwire - July 26, 2012) - Actelion Pharmaceuticals Canada Inc. announced today that the province of British Columbia has listed Toctino (alitretinoin) on its provincial formulary so that it is now eligible for reimbursement by PharmaCare for those patients suffering from severe chronic hand eczema.

TOCTINO (alitretinoin) is indicated for the treatment of severe chronic hand eczema refractory to high potency topical corticosteroids in adults. In clinical trials, alitretinoin was studied in a patient population who had previously failed standard therapy. Responses, defined as clear or almost clear hands, were achieved in up to 48% of patients, with up to 75% median reduction in disease signs and symptoms.

According to Dr. Chih-ho Hong, Clinical instructor of dermatology at the University of British Columbia, "Toctino (alitretinoin) is an important addition, helping dermatologists in their efforts to treat and manage this patient population. Many patients end up not responding to standard therapies and eventually get discouraged. Toctino offers them another realistic chance to get clear, normal hands for the first time in years."

Amanda Cresswell-Melville, Executive Director for the Eczema Society of Canada says: "Severe chronic hand eczema is truly impacting the quality of life of many Canadians. Dermatologists have done their best so far, but hopefully the availability of a drug like Toctino (alitretinoin) will signal the start of a new, more effective approach to help these patients."

Chronic hand eczema is a disease which affects up to six percent of the Canadian population, impacting personal, social and professional aspects of their lives, sometimes leading to a change of occupation and even unemployment.

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland and its Canadian office in Laval, Quebec. Actelion is committed to the discovery, development and commercialization of innovative treatments to serve areas of high unmet medical needs. Actelion Pharmaceuticals Canada Inc. is involved in respirology, rheumatology, cardiology, lysosomal storage disorders and dermatology. For more information on Actelion, please go to: www.actelion.com

Contact Information

  • Reggie Downey
    Director of Marketing
    Actelion Pharmaceuticals Canada Inc.
    1-866-531-4885 or (450) 681-1664
    www.actelion.com